hC Bioscience
HC Bioscience is dedicated to transforming patients' lives through innovative tRNA-based therapeutics that target genetically defined diseases and cancer. Their platform utilizes engineered tRNAs to correct genetic mutations, enabling the production of full-length, functional proteins. The company's mission is to develop first-in-class therapies that address a broad spectrum of genetic disorders, with a focus on precision medicine and gene-agnostic approaches.
Industries
Nr. of Employees
small (1-50)
hC Bioscience
645 Summer Street, Suite 102, Boston, MA 02210
Products
Liver-targeted anticodon-engineered tRNA candidate for restoration of Factor VIII
A development-stage anticodon-engineered tRNA delivered via lipid nanoparticle designed to suppress nonsense mutations in the Factor VIII transcript and restore synthesis of full-length, functional Factor VIII protein for severe hemophilia A.
Program applying anticodon-engineered tRNAs to Duchenne muscular dystrophy (PTC suppression)
Preclinical program delivering anticodon-engineered tRNAs to muscle cells to suppress premature termination codons in dystrophin mRNA and restore production of full-length dystrophin protein.
Oncology program to restore tumor suppressor proteins using engineered tRNAs
Preclinical tRNA-based oncology candidates designed to suppress nonsense mutations in tumor suppressor genes (e.g., APC) to restore full-length protein expression and inhibit tumor growth.
Liver-targeted anticodon-engineered tRNA candidate for restoration of Factor VIII
A development-stage anticodon-engineered tRNA delivered via lipid nanoparticle designed to suppress nonsense mutations in the Factor VIII transcript and restore synthesis of full-length, functional Factor VIII protein for severe hemophilia A.
Program applying anticodon-engineered tRNAs to Duchenne muscular dystrophy (PTC suppression)
Preclinical program delivering anticodon-engineered tRNAs to muscle cells to suppress premature termination codons in dystrophin mRNA and restore production of full-length dystrophin protein.
Oncology program to restore tumor suppressor proteins using engineered tRNAs
Preclinical tRNA-based oncology candidates designed to suppress nonsense mutations in tumor suppressor genes (e.g., APC) to restore full-length protein expression and inhibit tumor growth.
Services
Collaborative R&D, platform access, and strategic partnering to co-develop or license tRNA-based therapeutics and delivery solutions.
Collaborative R&D, platform access, and strategic partnering to co-develop or license tRNA-based therapeutics and delivery solutions.
Expertise Areas
- tRNA therapeutic discovery and engineering
- Delivery and formulation for nucleic acid therapeutics
- Preclinical in vivo pharmacology and tumor models
- CMC and downstream process development for polynucleotides
Key Technologies
- Anticodon-engineered tRNA therapeutics
- Lipid nanoparticle (LNP) delivery
- High-throughput tRNA sequencing and modification profiling (MSR-seq-style)
- Conjugate-based extra-hepatic delivery approaches
News & Updates
Supporting its program in Duchenne muscular dystrophy (DMD), HC Bioscience presented preclinical data demonstrating that delivery of anticodon engineered (ACE) tRNAs to muscle cells restores production of full-length, native dystrophin despite the presence of a premature termination codon (PTC). The data suggest potential for treating DMD, a fatal neuromuscular disease caused by mutations affecting dystrophin.
HC Bioscience announced the appointment of Simon Tsang, Ph.D., as Chief Business Officer. Dr. Tsang will lead business development efforts, focusing on advancing the company's portfolio of therapeutic tRNAs. He brings over 20 years of experience in program development, strategic planning, and deal-making in the biotech industry.
HC Bioscience's preclinical studies show promising results in restoring full-length tumor suppressor proteins and inhibiting tumor growth in models of colorectal cancer, hemophilia A, and Duchenne muscular dystrophy, highlighting the platform's broad therapeutic potential.
Supporting its program in Duchenne muscular dystrophy (DMD), HC Bioscience presented preclinical data demonstrating that delivery of anticodon engineered (ACE) tRNAs to muscle cells restores production of full-length, native dystrophin despite the presence of a premature termination codon (PTC). The data suggest potential for treating DMD, a fatal neuromuscular disease caused by mutations affecting dystrophin.
HC Bioscience announced the appointment of Simon Tsang, Ph.D., as Chief Business Officer. Dr. Tsang will lead business development efforts, focusing on advancing the company's portfolio of therapeutic tRNAs. He brings over 20 years of experience in program development, strategic planning, and deal-making in the biotech industry.
HC Bioscience's preclinical studies show promising results in restoring full-length tumor suppressor proteins and inhibiting tumor growth in models of colorectal cancer, hemophilia A, and Duchenne muscular dystrophy, highlighting the platform's broad therapeutic potential.